Vertex Pharmaceuticals has been attracting investor attention due to strong recent stock performance. The company's shares ...

Advocacy groups and trade associations are blanketing the Hill to elevate their priorities in the looming tax fight.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Handelsbanken Fonder AB reduced its stake in Vertex Pharmaceuticals by 28.1% in Q4, selling 115,479 shares. The fund now owns ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a ...

RAD Security, a San Francisco-based provider of security for cloud-focused infrastructure, raised $14 million in Series A ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...